Finally, regarding immunomodulatory activity, which could allow the reactivation of the immune response against cancer cells, Zhang et al.69 verified that co-administration of regorafenib with chimeric antigen receptor (CAR)-modified NK-92 cells (CAR-NK-92) with specificity against epithelial cell adhesion molecule (EpCAM) displays beneficial anti-cancer properties in EpCAM-positive HCT8 tumor xenografts. Here, EPCAM is linked to neoplasm.